Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

21 de março de 2014 atualizado por: National Cancer Institute (NCI)

A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial is studying how well giving CCI-779 together with rituximab works in treating patients with relapsed or refractory mantle cell lymphoma. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving CCI-779 together with rituximab may kill more cancer cells

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

PRIMARY OBJECTIVES:

I. Determine the overall response rate in patients with relapsed or refractory mantle cell lymphoma treated with CCI-779 and rituximab.

II. Determine the tolerability of this regimen in these patients by assessing toxicity.

SECONDARY OBJECTIVES:

I. Determine the time to disease progression and overall survival of patients treated with this regimen.

II. Determine the duration of response in patients treated with this regimen.

OUTLINE: Patients are stratified according to prior response to rituximab (sensitive [partial response (PR) or complete response (CR) that lasted ≥ 6 months after the last treatment with rituximab alone or in combination with chemotherapy] vs refractory [stable or progressive disease OR a PR or CR that lasted < 6 months after the last treatment with rituximab alone or in combination with chemotherapy]).

Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.

After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years.

Tipo de estudo

Intervencional

Inscrição (Real)

71

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Alabama
      • Mobile, Alabama, Estados Unidos, 36607
        • Mobile Infirmary Medical Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012
        • The Medical Center of Aurora
      • Boulder, Colorado, Estados Unidos, 80301
        • Boulder Community Hospital
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Penrose-Saint Francis Healthcare
      • Denver, Colorado, Estados Unidos, 80210
        • Porter Adventist Hospital
      • Denver, Colorado, Estados Unidos, 80218
        • Presbyterian - Saint Lukes Medical Center - Health One
      • Denver, Colorado, Estados Unidos, 80220
        • Rose Medical Center
      • Denver, Colorado, Estados Unidos, 80218
        • Exempla Saint Joseph Hospital
      • Denver, Colorado, Estados Unidos, 80224-2522
        • Colorado Cancer Research Program CCOP
      • Denver, Colorado, Estados Unidos, 80204
        • Saint Anthony Central Hospital
      • Englewood, Colorado, Estados Unidos, 80110
        • Swedish Medical Center
      • Grand Junction, Colorado, Estados Unidos, 81502
        • Saint Mary's Hospital and Regional Medical Center
      • Greeley, Colorado, Estados Unidos, 80631
        • North Colorado Medical Center
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Sky Ridge Medical Center
      • Longmont, Colorado, Estados Unidos, 80501
        • Longmont United Hospital
      • Loveland, Colorado, Estados Unidos, 80539
        • McKee Medical Center
      • Pueblo, Colorado, Estados Unidos, 81004
        • Saint Mary Corwin Medical Center
      • Thornton, Colorado, Estados Unidos, 80229
        • North Suburban Medical Center
      • Wheat Ridge, Colorado, Estados Unidos, 80033
        • Exempla Lutheran Medical Center
    • Illinois
      • Aurora, Illinois, Estados Unidos, 60504
        • Rush - Copley Medical Center
      • Bloomington, Illinois, Estados Unidos, 61701
        • Saint Joseph Medical Center
      • Canton, Illinois, Estados Unidos, 61520
        • Graham Hospital Association
      • Carthage, Illinois, Estados Unidos, 62321
        • Memorial Hospital
      • Eureka, Illinois, Estados Unidos, 61530
        • Eureka Hospital
      • Galesburg, Illinois, Estados Unidos, 61401
        • Galesburg Cottage Hospital
      • Galesburg, Illinois, Estados Unidos, 61401
        • Galesburg Clinic
      • Havana, Illinois, Estados Unidos, 62644
        • Mason District Hospital
      • Hopedale, Illinois, Estados Unidos, 61747
        • Hopedale Medical Complex - Hospital
      • Joliet, Illinois, Estados Unidos, 60435
        • Joliet Oncology-Hematology Associates Limited
      • Kewanee, Illinois, Estados Unidos, 61443
        • Kewanee Hospital
      • Macomb, Illinois, Estados Unidos, 61455
        • Mcdonough District Hospital
      • Normal, Illinois, Estados Unidos, 61761
        • Community Cancer Center Foundation
      • Normal, Illinois, Estados Unidos, 61761
        • Bromenn Regional Medical Center
      • Ottawa, Illinois, Estados Unidos, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Ottawa, Illinois, Estados Unidos, 61350
        • Ottawa Regional Hospital and Healthcare Center
      • Pekin, Illinois, Estados Unidos, 61554
        • Pekin Cancer Treatment Center
      • Pekin, Illinois, Estados Unidos, 61554
        • Pekin Hospital
      • Peoria, Illinois, Estados Unidos, 61637
        • OSF Saint Francis Medical Center
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois CancerCare-Peoria
      • Peoria, Illinois, Estados Unidos, 61614
        • Proctor Hospital
      • Peoria, Illinois, Estados Unidos, 61603
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois Oncology Research Association CCOP
      • Peru, Illinois, Estados Unidos, 61354
        • Illinois Valley Hospital
      • Princeton, Illinois, Estados Unidos, 61356
        • Perry Memorial Hospital
      • Spring Valley, Illinois, Estados Unidos, 61362
        • Saint Margaret's Hospital
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Clinic-Urbana Main
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Foundation dba Carle Cancer Center
    • Indiana
      • Beech Grove, Indiana, Estados Unidos, 46107
        • Saint Francis Hospital and Health Centers
      • Michigan City, Indiana, Estados Unidos, 46360
        • Saint Anthony Memorial Health Center
      • Richmond, Indiana, Estados Unidos, 47374
        • Reid Hospital and Health Care Services
    • Iowa
      • Ames, Iowa, Estados Unidos, 50010
        • McFarland Clinic
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Estados Unidos, 52402
        • Saint Luke's Hospital
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Cedar Rapids Oncology Association
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Oncology Associates
      • Clive, Iowa, Estados Unidos, 50325
        • Medical Oncology and Hematology Associates-West Des Moines
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Estados Unidos, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Estados Unidos, 50309
        • Medical Oncology and Hematology Associates-Des Moines
      • Des Moines, Iowa, Estados Unidos, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, Estados Unidos, 50307
        • Mercy Capitol
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa Oncology Research Association CCOP
      • Des Moines, Iowa, Estados Unidos, 50314
        • Medical Oncology and Hematology Associates
      • Mason City, Iowa, Estados Unidos, 50401
        • Mercy Medical Center - North Iowa
      • Sioux City, Iowa, Estados Unidos, 51104
        • Saint Luke's Regional Medical Center
      • Sioux City, Iowa, Estados Unidos, 51101-1733
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, Estados Unidos, 51104
        • Mercy Medical Center-Sioux City
      • Sioux City, Iowa, Estados Unidos, 51101
        • Siouxland Hematology - Oncology Associates
    • Kansas
      • Anthony, Kansas, Estados Unidos, 67003
        • Hospital District Sixth of Harper County
      • Chanute, Kansas, Estados Unidos, 66720
        • Cancer Center of Kansas - Chanute
      • Dodge City, Kansas, Estados Unidos, 67801
        • Cancer Center of Kansas - Dodge City
      • El Dorado, Kansas, Estados Unidos, 67042
        • Cancer Center of Kansas - El Dorado
      • Fort Scott, Kansas, Estados Unidos, 66701
        • Cancer Center of Kansas - Fort Scott
      • Independence, Kansas, Estados Unidos, 67301
        • Cancer Center of Kansas-Independence
      • Kingman, Kansas, Estados Unidos, 67068
        • Cancer Center of Kansas-Kingman
      • Lawrence, Kansas, Estados Unidos, 66044
        • Lawrence Memorial Hospital
      • Newton, Kansas, Estados Unidos, 67114
        • Cancer Center of Kansas - Newton
      • Parsons, Kansas, Estados Unidos, 67357
        • Cancer Center of Kansas - Parsons
      • Pratt, Kansas, Estados Unidos, 67124
        • Cancer Center of Kansas - Pratt
      • Salina, Kansas, Estados Unidos, 67401
        • Cancer Center of Kansas - Salina
      • Wellington, Kansas, Estados Unidos, 67152
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, Estados Unidos, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Estados Unidos, 67208
        • Associates In Womens Health
      • Wichita, Kansas, Estados Unidos, 67214
        • Cancer Center of Kansas - Main Office
      • Wichita, Kansas, Estados Unidos, 67214
        • Via Christi Regional Medical Center
      • Wichita, Kansas, Estados Unidos, 67214
        • Wichita CCOP
      • Winfield, Kansas, Estados Unidos, 67156
        • Cancer Center of Kansas - Winfield
    • Michigan
      • Adrian, Michigan, Estados Unidos, 49221
        • Bixby Medical Center
      • Adrian, Michigan, Estados Unidos, 49221
        • Hickman Cancer Center
      • Ann Arbor, Michigan, Estados Unidos, 48106-0995
        • Saint Joseph Mercy Hospital
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • Michigan Cancer Research Consortium Community Clinical Oncology Program
      • Dearborn, Michigan, Estados Unidos, 48123
        • Oakwood Hospital
      • Detroit, Michigan, Estados Unidos, 48236
        • Saint John Hospital and Medical Center
      • Flint, Michigan, Estados Unidos, 48502
        • Hurley Medical Center
      • Flint, Michigan, Estados Unidos, 48532
        • Genesys Regional Medical Center
      • Jackson, Michigan, Estados Unidos, 49201
        • Allegiance Health
      • Lansing, Michigan, Estados Unidos, 48912
        • Sparrow Hospital
      • Livonia, Michigan, Estados Unidos, 48154
        • Saint Mary Mercy Hospital
      • Monroe, Michigan, Estados Unidos, 48162
        • Mercy Memorial Hospital
      • Monroe, Michigan, Estados Unidos, 48162
        • Community Cancer Center of Monroe
      • Pontiac, Michigan, Estados Unidos, 48341-2985
        • Saint Joseph Mercy Oakland
      • Port Huron, Michigan, Estados Unidos, 48060
        • Saint Joseph Mercy Port Huron
      • Saginaw, Michigan, Estados Unidos, 48601
        • Saint Mary's of Michigan
      • Warren, Michigan, Estados Unidos, 48093
        • Saint John Macomb-Oakland Hospital
    • Minnesota
      • Bemidji, Minnesota, Estados Unidos, 56601
        • Merit Care Clinic Bemidji
      • Burnsville, Minnesota, Estados Unidos, 55337
        • Fairview Ridges Hospital
      • Coon Rapids, Minnesota, Estados Unidos, 55433
        • Mercy Hospital
      • Duluth, Minnesota, Estados Unidos, 55805
        • Miller-Dwan Hospital
      • Duluth, Minnesota, Estados Unidos, 55805
        • Saint Mary's Medical Center
      • Duluth, Minnesota, Estados Unidos, 55805
        • Duluth Clinic CCOP
      • Edina, Minnesota, Estados Unidos, 55435
        • Fairview-Southdale Hospital
      • Fridley, Minnesota, Estados Unidos, 55432
        • Unity Hospital
      • Maplewood, Minnesota, Estados Unidos, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Estados Unidos, 55407
        • Abbott-Northwestern Hospital
      • Robbinsdale, Minnesota, Estados Unidos, 55422
        • North Memorial Medical Health Center
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
      • Saint Louis Park, Minnesota, Estados Unidos, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Louis Park, Minnesota, Estados Unidos, 55416
        • Metro-Minnesota CCOP
      • Saint Paul, Minnesota, Estados Unidos, 55102
        • United Hospital
      • Shakopee, Minnesota, Estados Unidos, 55379
        • Saint Francis Regional Medical Center
      • Waconia, Minnesota, Estados Unidos, 55387
        • Ridgeview Medical Center
      • Woodbury, Minnesota, Estados Unidos, 55125
        • Minnesota Oncology and Hematology PA-Woodbury
    • Montana
      • Billings, Montana, Estados Unidos, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, Estados Unidos, 59101
        • Northern Rockies Radiation Oncology Center
      • Billings, Montana, Estados Unidos, 59101
        • Montana Cancer Consortium CCOP
      • Billings, Montana, Estados Unidos, 59107-7000
        • Billings Clinic
      • Billings, Montana, Estados Unidos, 59107
        • Deaconess Medical Center
      • Billings, Montana, Estados Unidos, 59101
        • Hematology-Oncology Centers of the Northern Rockies PC
      • Bozeman, Montana, Estados Unidos, 59715
        • Bozeman Deaconess Hospital
      • Bozeman, Montana, Estados Unidos, 59715
        • Bozeman Deaconess Cancer Center
      • Butte, Montana, Estados Unidos, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, Estados Unidos, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Estados Unidos, 59405
        • Berdeaux, Donald MD (UIA Investigator)
      • Havre, Montana, Estados Unidos, 59501
        • Northern Montana Hospital
      • Helena, Montana, Estados Unidos, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Estados Unidos, 59901
        • Kalispell Regional Medical Center
      • Kalispell, Montana, Estados Unidos, 59901
        • Glacier Oncology PLLC
      • Kalispell, Montana, Estados Unidos, 59901
        • Kalispell Medical Oncology
      • Missoula, Montana, Estados Unidos, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Estados Unidos, 59804
        • Guardian Oncology and Center for Wellness
      • Missoula, Montana, Estados Unidos, 59801
        • Community Medical Hospital
      • Missoula, Montana, Estados Unidos, 59802
        • Montana Cancer Specialists
    • North Carolina
      • Rutherfordton, North Carolina, Estados Unidos, 28139
        • Rutherford Hospital
    • North Dakota
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Bismarck Cancer Center
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Mid Dakota Clinic
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Saint Alexius Medical Center
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Medcenter One Health Systems
      • Fargo, North Dakota, Estados Unidos, 58122
        • MeritCare Medical Group
      • Fargo, North Dakota, Estados Unidos, 58122
        • Meritcare Hospital
    • Ohio
      • Bowling Green, Ohio, Estados Unidos, 43402
        • Wood County Oncology Center
      • Dayton, Ohio, Estados Unidos, 45406
        • Good Samaritan Hospital - Dayton
      • Dayton, Ohio, Estados Unidos, 45409
        • Miami Valley Hospital
      • Dayton, Ohio, Estados Unidos, 45415
        • Samaritan North Health Center
      • Dayton, Ohio, Estados Unidos, 45405
        • Grandview Hospital
      • Dayton, Ohio, Estados Unidos, 45428
        • Veteran Affairs Medical Center
      • Dayton, Ohio, Estados Unidos, 45429
        • Dayton CCOP
      • Elyria, Ohio, Estados Unidos, 44035
        • Hematology Oncology Center Incorporated
      • Findlay, Ohio, Estados Unidos, 45840
        • Blanchard Valley Hospital
      • Franklin, Ohio, Estados Unidos, 45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Fremont, Ohio, Estados Unidos, 43420
        • Fremont Memorial Hospital
      • Greenville, Ohio, Estados Unidos, 45331
        • Wayne Hospital
      • Kenton, Ohio, Estados Unidos, 43326
        • Cole, Sharon, K. M.D. (UIA Investigator)
      • Kettering, Ohio, Estados Unidos, 45429
        • Kettering Medical Center
      • Lima, Ohio, Estados Unidos, 45804
        • Lima Memorial Hospital
      • Maumee, Ohio, Estados Unidos, 43537
        • Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
      • Maumee, Ohio, Estados Unidos, 43537-1839
        • Northwest Ohio Oncology Center
      • Maumee, Ohio, Estados Unidos, 43537
        • Saint Luke's Hospital
      • Oregon, Ohio, Estados Unidos, 43616
        • Saint Charles Hospital
      • Oregon, Ohio, Estados Unidos, 43616
        • Bayview Oncology Associates
      • Sandusky, Ohio, Estados Unidos, 44870
        • North Coast Cancer Care
      • Sandusky, Ohio, Estados Unidos, 44870
        • Firelands Regional Medical Center
      • Sylvania, Ohio, Estados Unidos, 43560
        • Flower Memorial Hospital
      • Tiffin, Ohio, Estados Unidos, 44883
        • Mercy Hospital of Tiffin
      • Toledo, Ohio, Estados Unidos, 43608
        • Saint Vincent Mercy Medical Center
      • Toledo, Ohio, Estados Unidos, 43614
        • University of Toledo
      • Toledo, Ohio, Estados Unidos, 43617
        • Toledo Community Hospital Oncology Program CCOP
      • Toledo, Ohio, Estados Unidos, 43606
        • The Toledo Hospital
      • Toledo, Ohio, Estados Unidos, 43623
        • Toledo Clinic
      • Toledo, Ohio, Estados Unidos, 43623
        • Stark, Michael, Edward. M.D. (UIA Investigator)
      • Toledo, Ohio, Estados Unidos, 43623
        • Mercy Cancer Center at Saint Anne Mercy Hospital
      • Troy, Ohio, Estados Unidos, 45373
        • Upper Valley Medical Center
      • Wauseon, Ohio, Estados Unidos, 43567
        • Fulton County Health Center
      • Wilmington, Ohio, Estados Unidos, 45177
        • Clinton Memorial Hospital
      • Xenia, Ohio, Estados Unidos, 45385
        • Greene Memorial Hospital
    • Pennsylvania
      • Allentown, Pennsylvania, Estados Unidos, 18105
        • Lehigh Valley Hospital
      • Danville, Pennsylvania, Estados Unidos, 17822-2001
        • Geisinger Medical Center
      • State College, Pennsylvania, Estados Unidos, 16801
        • Geisinger Medical Group
      • Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
        • Geisinger Wyoming Valley
    • South Carolina
      • Anderson, South Carolina, Estados Unidos, 29621
        • AnMed Health Hospital
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Spartanburg Regional Medical Center
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Upstate Carolina CCOP
    • South Dakota
      • Sioux Falls, South Dakota, Estados Unidos, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Estados Unidos, 57105
        • Avera McKennan Hospital and University Health Center
    • Virginia
      • Fredericksburg, Virginia, Estados Unidos, 22401
        • Fredericksburg Oncology Inc
    • Wyoming
      • Sheridan, Wyoming, Estados Unidos, 82801
        • Welch Cancer Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Histologically confirmed* mantle cell lymphoma (MCL)

    • Relapsed, refractory, or stable disease after prior treatment
    • Tumor must be cyclin D-1 by immunohistochemistry OR 11;14 translocation by fluorescent in situ hybridization or cytogenetics

  • Measurable disease, defined as ≥ 1 of the following:

    • Unidimensionally measurable lymph node or tumor mass ≥ 2 cm by CT scan or MRI
    • Splenic enlargement if spleen is palpable ≥ 3 cm below the left costal margin
    • Malignant lymphocytosis if absolute lymphocytic count ≥ 5,000 AND lymphocytes confirmed to be monoclonal by flow cytometry
  • No known central nervous system involvement (e.g., parenchymal mass or leptomeningeal involvement)
  • Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
  • At least 3 months
  • No other concurrent treatment for MCL
  • Absolute neutrophil count ≥ 1,000/mm^3
  • Platelet count ≥ 75,000/mm^3
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Direct bilirubin < 1.5 times ULN
  • Aspartate aminotransferase (AST) ≤ 3 times ULN (5 times ULN if liver involvement by MCL is present)
  • Creatinine ≤ 2 times ULN
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study treatment
  • Cholesterol ≤ 350 mg/dL
  • Fasting triglycerides < 400 mg/dL
  • No known HIV positivity
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study compliance
  • No other uncontrolled illness
  • No other active malignancy requiring treatment OR that would preclude assessment of response to study drugs
  • Prior biologic response modifiers allowed
  • Prior immunotherapy allowed
  • Prior high-dose therapy with stem cell support (i.e., stem cell transplantation) allowed
  • No concurrent prophylactic growth factor to support neutrophils
  • Prior chemotherapy allowed
  • No other concurrent chemotherapy

  • No concurrent corticosteroids to induce an antitumor response

    • Concurrent corticosteroids (≤ 10 mg/day of prednisone or equivalent) for adrenal insufficiency or acute allergic reactions allowed
  • Prior radiotherapy allowed
  • No prior treatment with a mammalian target of rapamycin (mTOR) inhibitor
  • No other concurrent investigational or commercial agents or therapies for MCL
  • No other concurrent immunosuppressive therapy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm I
Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.
Biológico: rituximab
375 mg/m^2 Given IV
Outros nomes:
  • Rituxan
  • Mabthera
  • IDEC-C2B8
  • Anticorpo monoclonal IDEC-C2B8
  • MOAB IDEC-C2B8
Medicamento: temsirolimus
25 mg given IV
Outros nomes:
  • Torisel
  • CCI-779
  • inibidor do ciclo celular 779

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria
Prazo: Up to 12, 28-day cycles.

Complete Response (CR) - Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms.

Partial Response (PR) requires a >=50% decrease in sum of the products of the greatest dimension (SPD) of the six largest dominant nodes or nodal masses.

Overall Response Rate (ORR) - The number of patients who achieve a CR or PR divided by the total number of evaluable patients.

We report the Overall Response Rate here.
Up to 12, 28-day cycles.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to Progression
Prazo: Patients were followed up to five years after registration.
Time to progression was defined as the time from registration to the date of progression. Patients who died without disease progression were censored at the date of their last evaluation. Patients who were still receiving treatment at the time of these analyses were censored at the date of their last evaluation. The distribution of this time-to-event end point was estimated using the Kaplan-Meier method.
Patients were followed up to five years after registration.
Duration of Response
Prazo: Response duration is followed up to 5 years from registration.
Duration of response was defined as the time from the date of documented response to the date of progression. Patients who went off treatment due to other reasons (eg, adverse reactions, refusal of further treatment) were censored at that time. The distribution of this time-to-event end point was estimated using the Kaplan-Meier method.
Response duration is followed up to 5 years from registration.
Toxicity
Prazo: Assessed during treatment (up to 12, 28-day cycles)

As per the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 3, toxicity was defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment by the treating physician.

In this section, we report the number of participants that experienced at least one Grade 3 or higher adverse event.
Assessed during treatment (up to 12, 28-day cycles)
Overall Survival
Prazo: Patients were followed for survival status for up to 5 years.
Overall survival (OS) was defined as the time from registration to death resulting from any cause. The distribution of this time-to-event end point was estimated using the Kaplan-Meier method.
Patients were followed for survival status for up to 5 years.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

National Cancer Institute (NCI)

Investigadores

  • Investigador principal: Stephen Ansell, North Central Cancer Treatment Group

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de maio de 2005

Conclusão Primária (Real)

1 de setembro de 2009

Conclusão do estudo (Real)

1 de março de 2012

Datas de inscrição no estudo

Enviado pela primeira vez

3 de maio de 2005

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de maio de 2005

Primeira postagem (Estimativa)

4 de maio de 2005

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

17 de abril de 2014

Última atualização enviada que atendeu aos critérios de controle de qualidade

21 de março de 2014

Última verificação

1 de dezembro de 2013

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • NCI-2009-00644
  • U10CA025224 (Concessão/Contrato do NIH dos EUA)
  • N038H
  • CDR0000425334 (Identificador de registro: PDQ (Physician Data Query))

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em rituximab

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Paraguay

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever